Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Etherna Immunotherapies N.V.
BioCentury | Feb 7, 2025
Discovery & Translation
Science Spotlight: New protein degradation mechanism
BioCentury’s roundup of translational innovations also includes new insight into repeat expansion in Huntington’s and 10 new products
BioCentury | Sep 13, 2024
Data Byte
PanTera largest Belgian A round to date
Only nine other biotechs have raised over $25 million since 2015
BioCentury | Jul 10, 2024
Management Tracks
Pfizer seeking successor as Dolsten prepares to step down from R&D role
Plus: Lexicon, Pathios and Xeris name new CEOs, and updates from Jazz, AgomAb, VectorY, eTheRNA and more
BioCentury | Oct 18, 2023
Management Tracks
eTheRNA names Sagaert CEO, Dekkers as chairman
Plus: Cyrus Harmon becomes CEO at Vilya, and updates from Epic Bio, Exscientia, Pliant, Cognito, Pattern
BioCentury | Sep 8, 2023
Management Tracks
Greig named non-executive chair at Nucleome
Plus: updates from SparX, Breathe, Find and MedinCell
BioCentury | Jun 8, 2023
Management Tracks
New CFO, commercial officer at Pulmocide
Plus: Helmling named CBO at eTheRNA, and updates from EpimAb, Ring, Amarna, XNK and more
BioCentury | Dec 15, 2022
Management Tracks
Debra Yu leaving LianBio
Plus: Bayer vet Weinand appointed chair at Umoja, and updates from vTv, Gradalis, Generate and more
BioCentury | Oct 19, 2022
Management Tracks
New chairs at SomaLogic, Anjarium
Plus Dechamps becomes CEO at Bioxodes, and updates from Abalos, M2Gen and Orion
BioCentury | Aug 23, 2022
Regulation
Aug. 23 Quick Takes: Clinical hold sinks Foghorn
Plus Third Harmonic consider IPO, eTheRNA raises €39M and updates from Gate, Freedom and more
BioCentury | Feb 4, 2022
Product Development
Feb. 3 Quick Takes: Roche culls its oncology pipeline
Plus eTheRNA, Merck KGaA in mRNA deal, Novavax scores another approval and more
Items per page:
1 - 10 of 23